Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15050672 | 0.88 | NPC1 (0.41) | NPC1MAPTF11KLKB1DGAT1 | |
| SCHEMBL15050722 | 0.85 | NPC1 (0.40) | NPC1MAPTF11KLKB1DGAT1 | |
| SCHEMBL15051277 | 0.74 | AAK1 (0.43) | — | |
| SCHEMBL15050692 | 0.74 | AAK1 (0.41) | NPC1 | |
| SCHEMBL31416717 | 0.73 | NPC1 (0.41) | NPC1MAPTDGAT1 | |
| SCHEMBL25254238 | 0.69 | NPC1 (0.40) | NPC1MAPTF11KLKB1DGAT1 | |
| SCHEMBL6723774 | 0.69 | NPC1 (0.37) | NPC1MAPTF11 | |
| SCHEMBL25346960 | 0.68 | NPC1 (0.47) | NPC1MAPTF11 | |
| SCHEMBL20597948 | 0.68 | NPC1 (0.39) | NPC1MAPTF11KLKB1DGAT1 | |
| SCHEMBL30983254 | 0.68 | NPC1 (0.51) | NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2793879-A1 | HETEROARYLS AND USES THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013096637-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096637-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | PIK3R5, PIK3R4, PIK3C2B | NPC1 304/4885MKNK2 1204/4885MAPT 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.